PBOSLEDeucravacitinib
…r PBO) were enrolled in the 3-year LTE ( figure 1). Patients on PBO were rerandomized 1:1:1 to deucravacitinib (blinded); those on …
1articles mentioning treatments
1treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: PBO ×
PBO
This treatment is selected. Its supporting articles are shown below.